Canada markets close in 3 hours 17 minutes

Revive Therapeutics Ltd. (RVVTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3413-0.0178 (-4.96%)
As of 12:25PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.3591
Open0.3508
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3410 - 0.3708
52 Week Range0.1200 - 0.5100
Volume239,168
Avg. Volume595,455
Market Cap109.447M
Beta (5Y Monthly)-0.42
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

    FDA accepts Company’s Data Access Plan to determine potential new clinical endpoints to support Emergency Use AuthorizationTORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical tri

  • GlobeNewswire

    Revive Therapeutics Advances Inflammatory Liver Disorders Programs for Autoimmune Hepatitis and Liver Transplantation

    WHO reports 650 probable cases of acute hepatitis of unknown aetiology in children from 33 countries Company received FDA orphan drug designation for Bucillamine in the prevention of ischemia-reperfusion injury during liver transplantation and Cannabidiol for autoimmune hepatitis Company intends to move its head office to the US to better support growing drug programs with Bucillamine, Cannabidiol, and Psilocybin TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the

  • GlobeNewswire

    PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update

    Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion product, ketamine microneedle patch and ketamine wearable pump device for mental health, neurological, and pain disorders Seeking FDA approval for KETARX™ (ketamine injection and infusion product) for anesthesia and procedural sedation TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM)